Global Narcolepsy Treatment Market Set to Reach USD 6.67 Billion by 2028 at a 5.7% of CAGR, Driven by Advancements in Care and Growing Awareness

The global narcolepsy treatment market, valued at USD 4.77 billion in 2022, is projected to expand significantly, reaching USD 6.67 billion by 2028. This growth represents a Compound Annual Growth Rate (CAGR) of 5.7% during the forecast period from 2022 to 2028.

The rise in the global narcolepsy treatment market is primarily driven by increasing awareness about the condition, along with advancements in treatment options and healthcare infrastructure. Narcolepsy, a neurological disorder that affects sleep-wake cycles, has long been underdiagnosed, but growing recognition of its impact on patients’ lives is fueling demand for effective therapies.

Pharmaceutical innovations in narcolepsy medications, along with improved diagnostic techniques, are expected to drive further market growth. Additionally, the increasing focus on personalized medicine and new therapeutic approaches are enhancing the prospects of the market.

The growing prevalence of sleep disorders and the expanding number of healthcare providers offering specialized care are further supporting market expansion. As treatment options improve and awareness spreads, the narcolepsy treatment market is set for continued growth.

Key Insights

The growth of the narcolepsy treatment market is driven by several factors:

• Increasing Awareness: There is a growing recognition of narcolepsy as a serious sleep disorder, leading to more patients seeking diagnosis and treatment.
• Advancements in Treatment Options: The development of new medications and therapies aimed at managing symptoms of narcolepsy is enhancing treatment accessibility and effectiveness.

Growth Drivers

Several factors contributing to the market’s expansion include:

• Rising Incidence of Sleep Disorders: The increasing prevalence of narcolepsy and other sleep disorders is driving demand for effective treatment solutions.
• Research and Development: Ongoing research into the underlying causes and potential treatments for narcolepsy is expected to yield new therapies that can improve patient outcomes.

Regional Insights

• The North American market is expected to dominate due to high healthcare spending and advanced medical infrastructure.
• Emerging markets in Europe and Asia-Pacific are also anticipated to witness significant growth as awareness about sleep disorders increases.

Competitive Landscape

Key players in the narcolepsy treatment market focus on the acquisition of biopharmaceutical companies and possess a large pipeline for new molecular entities. Key players also collaborate and form alliance for product development and commercialization. Furthermore, major players focus on geographic expansion through inorganic growth strategy.

• In January 2020, Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, entered into an agreement with Pfizer Inc. for an exclusive U.S. license to Pfizer’s clinical and nonclinical data, and intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12 which Axsome is developing for the treatment of narcolepsy.
• In November 2020, Royal Philips, a global leader in health technology, announced the launch of Philips Ventilator BiPAP A40 EFL. With the introduction of this non-invasive ventilator, Philips extended its homecare solutions with a new ventilation therapy feature for chronic obstructive pulmonary disease (COPD) patients to breathe easier.

Key Companies Profiled

• ResMed Inc.
• Koninklijke Philips N.V.
• Merck & Co. Inc.
• Drive DeVilbiss Healthcare LLC
• GlaxoSmithKline Plc.
• Fisher & Paykel Healthcare Limited
• Pfizer Inc.

Grab Your Complete Report Instantly

Key Market Segments Covered in Narcolepsy Treatment Market Research

By Product:

• Narcolepsy Treatment Drugs
  • Modafinil
  • Sodium Oxybate
  • Armodafinil
  • Others
• Devices
  • CPAP Devices
  • BiPAP Devices
  • APAP Devices

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• e-commerce
• Drug Stores
• Others

By Region:

• North America
• Latin America
• Europe
• APAC
• MEA

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube